General health issues in multiple sclerosis: Comorbidities, secondary conditions, and health behaviors

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 4, 2013, Pages 1046-1057

  Marrie, Ruth Ann ^a,b   Hanwell, Heather ^c  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA INTERFERON; COLECALCIFEROL; CORTICOSTEROID; ERGOCALCIFEROL; GABAPENTIN; OPIATE; PRAMIPEXOLE; VITAMIN D;

ANXIETY DISORDER; ARTHRITIS; BIPOLAR DISORDER; BONE STRENGTH; CENTRAL SLEEP APNEA SYNDROME; CHRONIC LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISABILITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; EXPANDED DISABILITY STATUS SCALE; FRACTURE; HEALTH BEHAVIOR; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; IRRITABLE COLON; ISCHEMIC HEART DISEASE; LUNG DISEASE; MANIA; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEOPLASM; OBESITY; OCCUPATIONAL THERAPY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEPTIC ULCER; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PREVALENCE; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SUICIDE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; BONE DENSITY CONSERVATION AGENTS; FEMALE; HEALTH BEHAVIOR; HUMANS; MENTAL DISORDERS; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; OVERWEIGHT; RISK FACTORS; RISK-TAKING; SEDENTARY LIFESTYLE; SLEEP DISORDERS; VITAMIN D;

EID: 84881639003     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000433284.07844.6b     Document Type: Review

References (42)

1. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 2010;9(8):820-828.
2. Feinstein A. Multiple sclerosis and depression. Mult Scler 2011;17(11):1276-1281.
3. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13(1):67-72.
4. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology 2005;65(7): 1123-1125.
5. Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry 2010;22(1): 14-21.
6. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol 2006;253(2):219-223.
7. Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler 2007;13(2):215-219.
8. Langer-Gould A, Albers K, Van Den Eeden S, Nelson L. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010;16(7):855-861.
9. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33(3-4):197-207.
10. Marrie R, Yu B, Leung S, et al. The incidence and prevalence of thyroid disease do not differ in the MS and general populations: a validation study using administrative data. Neuroepidemiology 2012;39(2):135-142.
11. Caminero A, Bartolome M. Sleep disturbances in multiple sclerosis. J Neurol Sci 2011;309(1-2):86-91.
12. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 2010;14(2):121-129.
13. Bazelier MT, van Staa T-P, Uitdehaag BMJ, et al. A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology 2012;79(9): 922-928.
14. Bazelier MT, de Vries F, Bentzen J, et al. Incidence of fractures in patients with multiple sclerosis: the Danish National Health Registers. Mult Scler 2012;18(5): 1609-1619.
15. Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis. Neurology 2012;78(24): 1967-1973.
16. Bazelier MT, van Staa T, Uitdehaag BM, et al. The risk of fracture in patients with multiple sclerosis: the UK general practice research. J Bone Miner Res 2011;26(9): 2271-2279.
17. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX in osteoporosis. Osteoporos Int 2010; 21(suppl 2):S407-S413.
18. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5):513-521.
19. Dobson R, Ramagopalan S, Giovannoni G. Bone health and multiple sclerosis. Mult Scler 2012;18(11):1522-1528.
20. Rauch F, Plotkin H, DiMeglio L, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 2008;11(1):22-28.
21. Hanwell HE, Banwell B. Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta 2011;1812(2):202-212.
22. Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int 2011; 22(12):2935-2949.
23. Moen SM, Celius EG, Sandvik L, et al. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology 2011;77(2):151-157.
24. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62(11):1515-1526.
25. National Guideline Clearinghouse. Guideline synthesis: screening and risk assessment for osteoporosis. www.guideline.gov/syntheses/synthesis.aspx?id= 38658&search= guideline+synthesis%3a+screening+and+risk+assessment+for+osteoporosis. Accessed October 12, 2012.
26. Marrie RA, Horwitz RI, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72(2):117-124.
27. Dallmeijer AJ, Beckerman H, de Groot V, et al. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009;41(5):322-326.
28. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74(13): 1041-1047.
29. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30(3):233-267.
30. Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by Interferon-beta therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica 2012;125:91-95.
31. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res 2010;3:115-126.
32. Quesnel S, Feinstein A. Multiple sclerosis and alcohol: a study of problem drinking. Mult Scler 2004;10(2):197-201.
33. D'Hooghe MB, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012;19(4):616-624.
34. Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18(9):1334-1336.
35. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler 2008;14(1):35-53.
36. Motl RW, Pilutti LA. The benefits of exercise training in multiple sclerosis. Nat Rev Neurol 2012;8(9):487-497.
37. Vieth R. The pharmacology of vitamin D, including fortification strategies. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. San Diego, CA: Academic Press Inc, 2005:995-1015.
38. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press, 2011.
39. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010;9(11):709-715.
40. Looker AC. Body fat and vitamin D status in black versus white women. J Clin Endocrinol Metab 2005;90(2):635-640.
41. Steffensen LH, Brustad M, Kampman MT. What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year? J Neurol 2013;260(1): 182-188.
42. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74(23):1852- 1859.